What pharmacogenomic variants are known in TCF7L2?

Key variants in TCF7L2: rs12255372 (Intron 4 (G>T)), rs7903146 (Intron 3 (C>T)). These variants are associated with Type 2 diabetes, Impaired glucose tolerance, Beta-cell dysfunction.

Gene Database

TCF7L2 — Transcription Factor 7-Like 2

Q: What is the TCF7L2 gene?

TCF7L2 (Transcription Factor 7-Like 2) is located on chromosome 10q25.2. Key transcription factor in the Wnt signaling pathway. Regulates incretin hormone expression (GLP-1, GIP) and pancreatic beta-cell proliferation and function.

Q: Can PepFold design peptides targeting TCF7L2?

Yes. PepFold accepts rsIDs associated with TCF7L2, maps them to the protein structure, and generates peptide candidates. GLP-1 receptor agonist peptides (semaglutide class), incretin mimetics, and Wnt pathway modulator peptides. This is one of the most validated peptide therapeutic classes in medicine.

Chromosome 10q25.2

Key transcription factor in the Wnt signaling pathway. Regulates incretin hormone expression (GLP-1, GIP) and pancreatic beta-cell proliferation and function.

Pharmacogenomic Variants

rs12255372Risk factor

Intron 4 (G>T) — Type 2 diabetes

rs7903146Risk factor

Intron 3 (C>T) — Type 2 diabetes

Peptide Therapeutic Approaches

GLP-1 receptor agonist peptides (semaglutide class), incretin mimetics, and Wnt pathway modulator peptides. This is one of the most validated peptide therapeutic classes in medicine.

Related Therapeutics

Semaglutide (Ozempic/Wegovy)Liraglutide (Victoza)Tirzepatide (Mounjaro)

Associated Conditions

Type 2 Diabetes

A metabolic disorder characterized by insulin resistance and progressive beta-cell dysfunction. TCF7L2 variants are the strongest common genetic risk factors. GLP-1 receptor agonist peptides have revolutionized treatment.

Analyze TCF7L2 variants with PepFold

Submit rs12255372, rs7903146 and get ranked peptide candidates in under 2 minutes.

Try Analysis View Pricing